Armata Pharmaceuticals announced the receipt of $3.7 million in additional non-dilutive funding from the U.S. Department of War to support Phase 3 development activities for AP-SA02, an intravenous multi-phage product candidate for treating complicated bacteremia caused by S. aureus. This amount represents the first specific allocation for Phase 3 execution under a broader award that previously provided $28.7 million, bringing cumulative non-dilutive support to approximately $32.4 million. The company operates in the biotechnology industry, developing pathogen-specific bacteriophage therapeutics.
